KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) Return on Sales (2019 - 2025)

Aurinia Pharmaceuticals' Return on Sales history spans 7 years, with the latest figure at 2.73% for Q4 2025.

  • For Q4 2025, Return on Sales rose 271.0% year-over-year to 2.73%; the TTM value through Dec 2025 reached 1.01%, up 99.0%, while the annual FY2025 figure was 1.01%, 99.0% up from the prior year.
  • Return on Sales reached 2.73% in Q4 2025 per AUPH's latest filing, up from 0.43% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 2.73% in Q4 2025 to a low of 55.12% in Q1 2021.
  • Average Return on Sales over 5 years is 3.46%, with a median of 0.26% recorded in 2023.
  • Peak YoY movement for Return on Sales: skyrocketed 144933bps in 2021, then fell -9bps in 2023.
  • A 5-year view of Return on Sales shows it stood at 1.42% in 2021, then surged by 36bps to 0.92% in 2022, then skyrocketed by 35bps to 0.6% in 2023, then soared by 104bps to 0.02% in 2024, then soared by 11352bps to 2.73% in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Return on Sales are 2.73% (Q4 2025), 0.43% (Q3 2025), and 0.31% (Q2 2025).